Alnylam Enjoys Autumn in Paris With hATTR Win Over Ionis
Executive Summary
Patisiran data impresses more than inotersen but Ionis is the first to file with a European submission.
You may also be interested in...
Win-Win For Alnylam And Dicerna With RNAi Trade Secrets Settlement
Although Dicerna needs to make some payments to Alnylam to settle a patent infringement case, the company has avoided an expensive court trial and is free to find partners for its early-stage RNAi therapeutics programs.
Keeping Track: A Little Bit Of (Nearly) Everything
The latest drug development news and highlights from our US FDA Performance Tracker.
Deal Watch: GSK Declines Option As Ionis' Inotersen Nears Finish Line
Ionis will file polyneuropathy candidate in US and EU on its own, while GSK de-emphasizes rare diseases. Aclaris buys Confluence in earn-out-heavy deal, and Galena undertakes reverse merger with Sellas.